Semaglutide
Ozempic · Wegovy · Rybelsus
Once-weekly GLP-1 receptor agonist. FDA-approved as Ozempic (T2D) and Wegovy (chronic weight management); Rybelsus is the oral SNAC tablet. STEP/SELECT describe branded pens, not a research cake. Not a recovery 15-mer. Do not stack with another GLP-1/GIP agonist.
Use-case scores
0–10 against the evidence we have, not a gym ranking. Hidden domains do not apply here.
- Metabolic / weight8.5/10
Approved obesity and T2D labels plus STEP and SELECT. Ceiling 9 for RCT/approval; haircut because lean-mass loss and GI dropout are part of the real-world score, and a compounded vial is not Wegovy.
Compound card
- Sequence
- GLP-1 analog (Aib8, Arg34, C18 diacid on Lys26)
- Class
- Once-weekly GLP-1 receptor agonist (Ozempic / Wegovy / Rybelsus)
- Formula
- C187H291N45O59
- Status
- FDA-approved
How it works
Semaglutide is a GLP-1 (Glucagon-Like Peptide-1) receptor agonist with 94% homology to native human GLP-1. It mimics the incretin hormone GLP-1, which is naturally released after eating. Its mechanism involves multiple pathways: (1) stimulating insulin secretion from pancreatic beta cells in a glucose-dependent manner, (2) suppressing glucagon release from alpha cells, (3) slowing gastric emptying to increase satiety, and (4) acting on hypothalamic appetite centers to reduce food intake.
Semaglutide has a 7-day half-life due to albumin binding and DPP-4 enzyme resistance, allowing once-weekly dosing. It is FDA-approved as Ozempic for type 2 diabetes, Wegovy for chronic weight management, and Rybelsus in oral formulation. Clinical trials (STEP program) demonstrated 15-17% body weight reduction at the 2.4 mg dose.
Source: FDA Label (Wegovy), PMID: 33567185 (STEP 1)
Goal context
Weight and glycemia, not a peptide stack mascot
The job is appetite, gastric emptying, and glucose-dependent insulin. That is why the scheduler exists. BPC-157 does not belong in the titration.
Pen vs cake
Ozempic and Wegovy are devices with a label. Compounded semaglutide is 503A/503B when legal. Research-chem is weaker still. Same amino-acid story, different factory.
Background & History
Semaglutide was developed by Novo Nordisk through systematic modification of native GLP-1 to resist DPP-4 degradation. Its C18 fatty acid chain enables albumin binding, extending half-life to 7 days. FDA-approved as Ozempic in 2017 for type 2 diabetes and as Wegovy in 2021 for chronic weight management - the first weight loss drug approved for obesity as a chronic disease. The STEP trial program (2021) demonstrated 15–17% body weight reduction, redefining obesity pharmacotherapy.
Key Clinical Metrics
Peak Weight Loss
Achieved at target maintenance dose (2.4mg) over 68 weeks.
Receptor Targets
94% human homology, single-receptor agonist.
Half-Life
Long duration of action strongly supports once-weekly administration.
Published Trial Data
Semaglutide 2.4 mg for Chronic Weight Management
Shown an average of 14.9% body weight reduction in adults with obesity over 68 weeks.
Semaglutide 2.4 mg in Type 2 Diabetes
Demonstrated 9.6% body weight reduction in adults with both obesity and type 2 diabetes.
Two-Year Effects of Semaglutide 2.4 mg
Confirmed sustained weight loss maintenance of 15.2% over 104 weeks without significant plateauing decay.
Cardiovascular Outcomes Trial
Reduced risk of major adverse cardiovascular events by 20% in adults with overweight/obesity and established CVD without diabetes.
Research Use Cases
- ✓Understanding Ozempic vs Wegovy vs Rybelsus vs a compounded cake
- ✓Why weekly titration exists (GI tolerance, not a secret stack)
- ✓Not a muscle-recomp peptide and not a NASH DIY protocol
Dosing
| Phase | Dose | Frequency | Notes |
|---|---|---|---|
| Initiation (Weeks 1-4) | 0.25 mg | once weekly | Ramp-up dose to assess GI tolerance. Not a therapeutic dose. |
| Escalation (Weeks 5-8) | 0.50 mg | once weekly | First therapeutic dose tier. |
| Escalation (Weeks 9-12) | 1.0 mg | once weekly | Standard maintenance for Ozempic (diabetes). Wegovy escalates further. |
| Maintenance (Wegovy max) | 2.4 mg | once weekly | Target for chronic weight management. |
Administration
Semaglutide: Branded pen (Ozempic / Wegovy) vs Compounded / research vial vs Rybelsus (oral SNAC tablet)
- Ozempic / Wegovy is the labeled device. STEP/SURMOUNT/label numbers describe this class of product, not a reconstituted cake.
- No reconstitution step. No BAC water. No fake 5 mg vial chart.
- Wegovy 2.4 mg weekly and Ozempic diabetes max are labeled schedules. STEP/SELECT describe the pen class.
- A pen is a prescription device. Compounded or research vials are not a cheaper Wegovy with the same factory.
- Pens do not go in the reconstitution calculator.
- If you actually have a cake, vial math is the job this site will do.
- Compounded semaglutide is 503A/503B when legal. Research-chem is weaker still.
- A cake is not the pen. Identity, sterility, and dose accuracy are on you and the compounder.
- Do not stack with another GLP-1/GIP agonist.
- Boxed-warning class (MTC/MEN2) still applies to the receptor, not only to the brand name.
- The only FDA-approved oral semaglutide. Real SNAC chemistry, not peptide-capsule folklore.
- No needle. No BAC water.
- Different schedule and a different F% than the pen. It is not a loophole Wegovy.
- Food and other oral meds wreck the already-tiny absorption window. Follow the insert.
- Same GLP-1 class warnings as the injectable products.
Timeline
Who it is for
Obesity / Chronic Weight Management
HighFDA-approved (Wegovy). Clinical STEP trials showed 15-17% average total body weight reduction.
Type 2 Diabetes
HighFDA-approved (Ozempic). Strong HbA1c reduction with secondary cardiovascular benefits (SUSTAIN-6, SELECT).
Reconstitution
| Vial | Water | Concentration | Example dose |
|---|---|---|---|
| Pen (Ozempic / Wegovy) | n/a (prefilled) | Device-labeled | Follow the pen click-chart. Do not recon a pen. |
| 5 mg compounded/research cake | 2.5 mL BAC | 2 mg/mL | 0.25 mg = 0.125 mL = 12.5 units on a U-100. This is not a Wegovy pen. |
Change vial size or water volume? Open the reconstitution calculator.
Safety & Considerations
Semaglutide is FDA-approved for type 2 diabetes and weight management. Common side effects include nausea, vomiting, diarrhea (usually transient during dose escalation). Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Not recommended during pregnancy.
Regulatory & Legal Status
FDA-approved as Ozempic® (T2D) and Wegovy® (obesity)
Not currently on the WADA 2026 Prohibited List. Policies may change - verify before competition.
Prescription Drug
US Compounding: Available via licensed pharmacy Rx
⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.
Limits of current evidence
- STEP/SELECT describe branded once-weekly semaglutide, not a 5 mg research cake.
- Weight loss includes lean mass. Protein and resistance work are the usual counter, not a secretagogue requirement on the label.
- Rybelsus is oral semaglutide with different bioavailability. Do not put a tablet in the reconstitution calculator.
- Do not stack with another GLP-1/GIP agonist.
Human evidence
Strong · labeled STEP / SELECT program
- Studies listed here:
- 4
- STEP 1: average 14.9% body weight reduction over 68 weeks at 2.4 mg (branded).
- STEP 2: 9.6% body weight reduction with type 2 diabetes.
- STEP 5: sustained ~15.2% over 104 weeks.
- SELECT: 20% relative reduction in major adverse cardiovascular events in adults with overweight/obesity and established CVD without diabetes.
- STEP/SELECT describe branded once-weekly semaglutide, not a 5 mg research cake.
Verdict
Semaglutide is a real, labeled incretin drug. Use a pen under a clinician for the STEP/SELECT job. Compounded or research vials are a different product class with the same receptor story and none of the device/pharmacovigilance. It is not a muscle-recomp peptide and not a recovery 15-mer.
Interactions & Contraindications
Contraindicated: personal/family history of medullary thyroid carcinoma or MEN2. Do not combine with other GLP-1 agonists or DPP-4 inhibitors (additive effects without clear benefit). May require insulin dose adjustment in T2D patients. Slowed gastric emptying affects absorption of oral medications - separate timing by 1 hour.
Synergies & Common Stacks
NOT a synergy - combining two GLP-1 agonists is contraindicated due to additive GI side effects and risk of hypoglycemia without additional benefit.
BPC-157's GI protective effects may help manage GLP-1-induced nausea and gastric slowing during dose escalation, supporting tolerability.
Semaglutide vs. Tirzepatide
Canonical comparison: Semaglutide vs Tirzepatide
| Attribute | Semaglutide | Tirzepatide |
|---|---|---|
| Mechanism | GLP-1 receptor agonist (single) | GIP + GLP-1 dual receptor agonist |
| Peak Weight Loss | 14.9–17% body weight (STEP trials) | 22.5% body weight (SURMOUNT-1) |
| FDA Approval | Ozempic® (T2D) / Wegovy® (obesity) | Mounjaro® (T2D) / Zepbound® (obesity) |
| Half-Life | ~7 days (once weekly) | ~5 days (once weekly) |
| GI Side Effects | Moderate - nausea most common | Similar profile; slightly more at peak dose |
| Starting Dose | 0.25 mg/week (escalated over 20 wks) | 2.5 mg/week (escalated over 20 wks) |
| Cost (branded) | ~$900–1,100/mo list price | ~$1,000–1,200/mo list price |
Verdict: Tirzepatide delivers greater weight loss due to its dual receptor mechanism; semaglutide has a longer clinical track record and broader global availability. For maximum weight loss, tirzepatide is the better choice; for established safety data, semaglutide leads.
Semaglutide vs. Liraglutide
Canonical comparison: Semaglutide vs Liraglutide
| Attribute | Semaglutide | Liraglutide |
|---|---|---|
| Mechanism | GLP-1 agonist | GLP-1 agonist (same class) |
| Peak Weight Loss | 14.9–17% | ~8% (SCALE trial) |
| Dosing Schedule | Once weekly injection | Daily injection |
| FDA Approval | Ozempic® / Wegovy® | Victoza® (T2D) / Saxenda® (obesity) |
| Cardiovascular | Proven CV risk reduction (SUSTAIN-6) | Proven CV risk reduction (LEADER) |
| Convenience | High - once weekly dosing | Low - daily injection required |
Verdict: Semaglutide is the clear successor to liraglutide: superior weight loss, once-weekly dosing convenience, and comparable safety profile. Liraglutide is primarily used today where semaglutide is unavailable or not covered.
Appears in goal guides
Goal guides are maps, not clinic protocols. A mention here is not a treatment plan.
Frequently Asked Questions
Pen or compounded vial?▼
What is the standard semaglutide dose escalation?▼
How do I calculate semaglutide syringe units?▼
Can I take semaglutide with other peptides?▼
What is the difference between Ozempic and Wegovy?▼
References
- Wilding et al. “"Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)".” New England Journal of Medicine (2021). PMID: 33567185
- Lincoff et al. “"Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT)".” New England Journal of Medicine (2023). PMID: 37952131
- Rodbard HW, et al. “Oral semaglutide versus empagliflozin in patients with type 2 diabetes (PIONEER 2).” Diabetes Care (2019). PMID: 31530667
- Marso SP, et al. “Semaglutide and cardiovascular outcomes in patients with type 2 diabetes.” N Engl J Med (2016). PMID: 27633186
📚 Related Articles
Get Semaglutide from our recommended source - independently tested, COA-verified, USP <85> endotoxin compliant. Use code 4SS6SFTUGB at checkout.
Affiliate link · Full review